首页 › 慢性粒单核细胞白血病 › 得克萨斯州 › Houston
Houston TX 慢性粒单核细胞白血病临床试验
16项针对 慢性粒单核细胞白血病的研究正在 Houston及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
招募中2 期
- The University of Texas MD Anderson Cancer Center, Houston
Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
招募中2 期
- M D Anderson Cancer Center, Houston
A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
招募中2 期欢迎健康志愿者
- MD Anderson Cancer Center, Houston
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
招募中2 期
- M D Anderson Cancer Center, Houston
Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia
招募中2 期
- MD Anderson Cancer Center, Houston
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
招募中2/3 期欢迎健康志愿者
- M D Anderson Cancer Center, Houston
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
招募中1/2 期
- M D Anderson Cancer Center, Houston
Personalized NK Cell Therapy in CBT
招募中2 期
- M D Anderson Cancer Center, Houston
Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)
招募中1/2 期
- The University of Texas M. D. Anderson Cancer Center, Houston
A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
招募中2 期
- M D Anderson Cancer Center, Houston
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
招募中1 期
- M D Anderson Cancer Center, Houston
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
招募中2/3 期
- MD Anderson Cancer Center, Houston
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
招募中1/2 期
- M D Anderson Cancer Center, Houston
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
招募中2 期
- MD Anderson, Houston
A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
招募中1 期
- MD Anderson Cancer Center, Houston
A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
招募中1 期
- MD Anderson Cancer Center, Houston
其他城市的 慢性粒单核细胞白血病试验
- Seattle, WA10 项研究
- Boston, MA7 项研究
- Mountain View, CA6 项研究
- Baldwin Park, CA6 项研究
- Rochester, MN6 项研究
- New York City, NY6 项研究
- Durham, NC5 项研究
- Miami, FL4 项研究
- Tampa, FL4 项研究
- Birmingham, AL4 项研究
- Columbus, OH4 项研究
- Atlanta, GA4 项研究
Houston的其他研究
- 非小细胞肺癌145 项研究
- 乳腺癌126 项研究
- 癌症（所有类型）121 项研究
- 转移性癌症104 项研究
- 结直肠癌102 项研究
- 卵巢癌89 项研究
- 急性髓系白血病85 项研究
- 肺癌78 项研究
- 前列腺癌76 项研究
- 子宫内膜癌68 项研究
- 胰腺癌61 项研究
- 黑色素瘤59 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。